Stay updated with breaking news from Radical Prostatectomy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) Director Karin Eastham sold 2,500 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $20.97, for a total transaction of $52,425.00. Following the completion of the transaction, the director now directly owns 33,125 shares of […]
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target […]
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 […]
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate...
Veracyte (NASDAQ:VCYT – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link. Veracyte (NASDAQ:VCYT – Get […]